Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ. Rosenstock J, et al. Among authors: ampudia blasco fj. Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13. Diabetes Obes Metab. 2018. PMID: 29974618 Free PMC article.
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Davies MJ, Leiter LA, Guerci B, Grunberger G, Ampudia-Blasco FJ, Yu C, Stager W, Niemoeller E, Souhami E, Rosenstock J. Davies MJ, et al. Among authors: ampudia blasco fj. Diabetes Obes Metab. 2017 Dec;19(12):1798-1804. doi: 10.1111/dom.12980. Epub 2017 Jul 7. Diabetes Obes Metab. 2017. PMID: 28432746 Free PMC article. Clinical Trial.
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Roussel R, d'Emden MC, Fisher M, Ampudia-Blasco FJ, Stella P, Bizet F, Cali AMG, Wysham CH. Roussel R, et al. Among authors: ampudia blasco fj. Diabetes Obes Metab. 2018 Feb;20(2):448-452. doi: 10.1111/dom.13071. Epub 2017 Sep 14. Diabetes Obes Metab. 2018. PMID: 28736942 Free PMC article. Clinical Trial.
Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.
Rosenstock J, Ampudia-Blasco FJ, Lubwama R, Peng XV, Boss A, Shi L, Fonseca V. Rosenstock J, et al. Among authors: ampudia blasco fj. Diabetes Obes Metab. 2020 Dec;22(12):2295-2304. doi: 10.1111/dom.14154. Epub 2020 Sep 2. Diabetes Obes Metab. 2020. PMID: 32729183 Free PMC article.
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.
Danne T, Edelman S, Frias JP, Ampudia-Blasco FJ, Banks P, Jiang W, Davies MJ, Sawhney S. Danne T, et al. Among authors: ampudia blasco fj. Diabetes Obes Metab. 2021 Mar;23(3):854-860. doi: 10.1111/dom.14271. Epub 2020 Dec 23. Diabetes Obes Metab. 2021. PMID: 33289297
Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study.
Wilmot EG, Close KL, Jurišić-Eržen D, Bruttomesso D, Ampudia-Blasco FJ, Bosnyak Z, Roborel de Climens A, Bigot G, Peters AL, Renard E, Berard L, Calliari LE, Seufert J. Wilmot EG, et al. Among authors: ampudia blasco fj. Diabetes Obes Metab. 2021 Aug;23(8):1892-1901. doi: 10.1111/dom.14416. Epub 2021 Jun 14. Diabetes Obes Metab. 2021. PMID: 33914401
75 results